ArticleJournal of neural transmission (Vienna, Austria : 1996)2010
Oxidative stress and plasma aminopeptidase activity in Huntington's disease.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Blood Oxidative Stress Marker Aberrations in Patients with Huntington's Disease: A Meta-Analysis Study.Oxidative medicine and cellular longevity · 2020Pooled it
- Oxidative Stress in Huntington's Disease.Biomolecules · 2025Review
- Recent Advances in the Synthesis of Antioxidant Derivatives: Pharmacological Insights for Neurological Disorders.Current topics in medicinal chemistry · 2024Review
- Association of Oxidative Stress with Neurological Disorders.Current neuropharmacology · 2022Article
- Detecting Oxidative Stress Biomarkers in Neurodegenerative Disease Models and Patients.Methods and protocols · 2020Article
- Reactive Species in Huntington Disease: Are They Really the Radicals You Want to Catch?Antioxidants (Basel, Switzerland) · 2020Review
- Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases.International journal of molecular sciences · 2019Review
- Review
- A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.Journal of Huntington's disease · 2018Review
- The Role of Reactive Oxygen Species in the Pathogenesis of Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease: A Mini Review.Oxidative medicine and cellular longevity · 2016Review
- Redox processes in neurodegenerative disease involving reactive oxygen species.Current neuropharmacology · 2012Article
- Protection by glia-conditioned medium in a cell model of Huntington disease.PLoS currents · 2012Article
- The proteome of the locus ceruleus in Parkinson's disease: relevance to pathogenesis.Brain pathology (Zurich, Switzerland) · 2012Article
- Huntington's disease and mitochondrial alterations: emphasis on experimental models.Journal of bioenergetics and biomembranes · 2010Article
- Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease.Journal of bioenergetics and biomembranes · 2010Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntington's disease (HD) is a genetic neurodegenerative disorder. Oxidative stress, mitochondrial dysfunction, and protein metabolism impairment have been implicated in its pathogenesis. However, the contribution of these phenomena to HD onset or progression is not well known, and they have been less studied in peripheral blood. We analyzed plasma lipid peroxide (LPO) and lactate (LAC) concentrations as indicators of oxidative stress and mitochondrial dysfunction in symptomatic HD patients (sHD) and asymptomatic HD gene carriers (aHD). We also measured the plasma activity of aminopeptidases (APs), an important group of proteolytic enzymes. LPO and LAC concentrations were significantly elevated in sHD patients but not in aHD carriers. Aspartate and glutamate AP activities were significantly reduced in sHD patients and aHD carriers. These findings demonstrate that sHD patients are under oxidative stress, which may favor progression of the disease. Plasma AP activity was decreased before the appearance of HD symptoms and oxidative stress and may be related to protein metabolism impairment. These results indicate that therapy directed to improve oxidative stress and normalize AP activity may be useful in the treatment of HD. They also suggest that decreased plasma AP activity in aHD carriers may predict the future onset of HD symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.